Slaughter and May is advising GHO Capital on the sale of VISUfarma to Lupin Limited

Slaughter and May is advising GHO Capital Partners, the European specialist investor in global healthcare, on the sale of VISUfarma to Lupin, the global pharmaceuticals company. 

VISUfarma was created by GHO Capital in 2016 by combining the founder-owned Italian VISUfarma with the European commercial operations of Nicox S.A.. Since its initial investment as part of Fund I, GHO has grown the business substantially into a pan-European leader of ophthalmology pharmaceuticals.

Completion of the transaction is conditional upon receipt of certain regulatory approvals and is expected to occur by the end of 2025.